Loading…
Lobbying Spend
—
Filings
65
Firms Hired
3
Active Period
2018–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1262
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Client expense: — · Firm income: $80,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1262
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Client expense: — · Firm income: $80,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act. Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1262
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act. Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21).
Client expense: — · Firm income: $80,000
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1262
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
Client expense: — · Firm income: $80,000
Matched citations: S. 932
Give Kids a Chance Act of 2024
2024 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 3433
Creating Hope Reauthorization Act of 2024
2024 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7384
Creating Hope Reauthorization Act of 2024
2024 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Client expense: — · Firm income: $80,000
Matched citations: S. 4583
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Client expense: — · Firm income: $80,000
Matched citations: H.R.3433
Creating Hope Reauthorization Act of 2024
2024 · third_quarter · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Client expense: — · Firm income: $80,000
Matched citations: H.R.7384
Creating Hope Reauthorization Act of 2024
2024 · third_quarter · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Client expense: — · Firm income: $80,000
Matched citations: S.4583
Creating Hope Reauthorization Act of 2024
2024 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384; 2. 4583 - A bill to amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7384
Creating Hope Reauthorization Act of 2024
2024 · first_quarter · Firm: TIBER CREEK GROUP
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7384
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: TIBER CREEK GROUP
Issues related to drug pricing in H.R. 5376 - the Build Back Better Act; Issues related to nursing home quality measurement.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Source: Senate LDA